Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Prime Medicine Inc shares valued at $20,000,000 were purchased by NELSEN ROBERT on Feb 15 ’24. At $6.25 per share, NELSEN ROBERT acquired 3,200,000 shares. The insider’s holdings grew to 3,200,000 shares worth approximately $13.15 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, ARCH Venture Partners XII, LLC purchased 3,200,000 shares, netting a total of over 20,000,000 in proceeds. Following the buying of shares at $6.25 each, the insider now holds 3,200,000 shares.
Before that, ARCH Venture Partners X, LLC had added 3,200,000 shares to its account. In a trade valued at $20,000,000, the 10% Owner bought Prime Medicine Inc shares for $6.25 each. Upon closing the transaction, the insider’s holdings increased to 3,200,000 shares, worth approximately $13.15 million.
As published in their initiating research note from H.C. Wainwright on May 20, 2024, Prime Medicine Inc [PRME] has been a Buy and the price target has been revised to $10. Analysts at Citigroup upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in mid May. As of April 22, 2024, Chardan Capital Markets has initiated its “Buy” rating for PRME. Earlier on April 08, 2024, TD Cowen initiated its rating. Their recommendation was “a Buy” for PRME stock.
Analyzing PRME Stock Performance
During the last five days, there has been a drop of approximately -6.59%. Over the course of the year, Prime Medicine Inc shares have dropped approximately -53.61%. Shares of the company reached a 52-week high of $9.77 on 02/27/24 and a 52-week low of $3.99 on 08/12/24. A 50-day SMA is recorded $5.71, while a 200-day SMA reached $6.77. Nevertheless, trading volume fell to 0.65 million shares from 0.5 million shares the previous day.
Support And Resistance Levels for Prime Medicine Inc (PRME)
According to the 24-hour chart, there is a support level at 3.98, which, if violated, would cause prices to drop to 3.84. In the upper region, resistance lies at 4.30. The next price resistance is at 4.48. RSI (Relative Strength Index) is 33.03 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.60, which suggests the price will decrease in the coming days. Percent R is at 93.88%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
